These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 35626357)
1. The Use of van de Weijer T; Broen MPG; Moonen RPM; Hoeben A; Anten M; Hovinga K; Compter I; van der Pol JAJ; Mitea C; Lodewick TM; Jacquerie A; Mottaghy FM; Wildberger JE; Postma AA Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626357 [TBL] [Abstract][Full Text] [Related]
2. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162 [TBL] [Abstract][Full Text] [Related]
3. Static Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
9. Recent Developments of 18F-FET PET in Neuro-oncology. Muoio B; Giovanella L; Treglia G Curr Med Chem; 2018; 25(26):3061-3073. PubMed ID: 29173147 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of O-(2-[ Kertels O; Kessler AF; Mihovilovic MI; Stolzenburg A; Linsenmann T; Samnick S; Brändlein S; Monoranu CM; Ernestus RI; Buck AK; Löhr M; Lapa C Mol Imaging Biol; 2019 Dec; 21(6):1174-1181. PubMed ID: 30977078 [TBL] [Abstract][Full Text] [Related]
11. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric Haubold J; Demircioglu A; Gratz M; Glas M; Wrede K; Sure U; Antoch G; Keyvani K; Nittka M; Kannengiesser S; Gulani V; Griswold M; Herrmann K; Forsting M; Nensa F; Umutlu L Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1435-1445. PubMed ID: 31811342 [TBL] [Abstract][Full Text] [Related]
12. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087 [TBL] [Abstract][Full Text] [Related]
15. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606 [TBL] [Abstract][Full Text] [Related]